Prostate cancer radiotherapy in Austria

Strahlentherapie und Onkologie

Volumn 187, Issue 5, 2011, Pages 279-283

  Goldner, Gregor ^a   Sljivic, Samir ^a   Oismueller, Renee ^b   Salinger, Johanna ^c   Mittermüller, Michael ^c   Langsenlehner, Tanja ^d   Harder, Walter ^e   Kametriser, Gerhard ^f   Eiter, Helmut ^g   Nechvile, Elisabeth ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DANUBE HOSPITAL   (Austria)

^c Landesklinikum ^*  (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e Institute of Diagnostic and Interventional Radiology   (Austria)

^f Salzburger Landeskliniken   (Austria)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

^h Messerli Institute   (Austria)

Author keywords

Austria; Number of patients; Overview; Prostate cancer; Radiotherapy

Indexed keywords

ADULT; AUSTRIA; BRACHYTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; REVIEW; THREE DIMENSIONAL IMAGING;

EID: 79960288051     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-011-2268-9     Document Type: Review

References (16)

1. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-8. (Pubitemid 41140332)
2. Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard- dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
3. Deutsche Gesellschaft für Urologie (DGU) S3-Leitlinie Prostatakarzinom, Version 1.0, September 2009.
4. Fairley L, Baker M, Whiteway J et al. Trends in non-metastatics prostate cancer management in the Northern and Yorkshire region of England, 2000-2006. Br J Cancer 2009;101:1839-45.
5. Gatta G, Zigon G, Buemi A et al. Prostate cancer in Europe at the end of 1990s. Acta Oncologica 2009;48:867-73.
6. Goldner G, Bombosch V, Geinitz H et al. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol 2009;185:94-100.
7. Goldner G, Dimopoulos J, Kirisits C et al. Moderate dose escalation in threedimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 2009;185:438-45.
8. Guckenberger M, Flentje M. Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol 2007;183:57-62.
9. Guckenberger M, Ok S, Polat B et al. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol 2010;186: 535-43.
10. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
11. Peeters STH, Heemsbergen WD, Koper PCM et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. (Pubitemid 46622106)
12. Statistik Austria. Statistisches Jahrbuch 2009. (http://www.statistik.at) .
13. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-35. (Pubitemid 44749360)
14. Vordermark D, Marold D, Wirth S et al. Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998-2000. Strahlenther Onkol 2007;183:314-20. (Pubitemid 46996070)
15. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30.
16. Yoshioka Y, Suzuki O, Kobayashi K et al. External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification. Strahlenther Onkol 2009;185:446-52.